TheraSphere With Durvalumab and Tremelimumab for HCC
A phase 2 trial of Durvalumab in hepatocellular carcinoma, run by Boston Scientific Corporation, active and no longer recruiting.
Overview
TheraSphere With Durvalumab and Tremelimumab for HCC is a phase 2 interventional study registered as NCT05063565 by Boston Scientific Corporation, with 100 participants planned, started 2023-11-03 and due to reach its primary completion in 2027-06. Interventions recorded: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Durvalumab, Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.
- AgentYttrium-90 glass microspheres
Shares Boston Scientific, Hepatocellular carcinoma, Yttrium-90.
- CompanySirtex Medical
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.
- IndicationIntermediate hepatocellular carcinoma (BCLC B)
Shares Durvalumab, Hepatocellular carcinoma, Yttrium-90.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Hepatocellular carcinoma, Yttrium-90.
- CompanyQuirem Medical
Shares Boston Scientific, Hepatocellular carcinoma, Yttrium-90.
- TrialSARAH and SIRveNIB
Shares Hepatocellular carcinoma, Yttrium-90.
- TechnologyRadioembolisation (TARE / SIRT, yttrium-90)
Shares Boston Scientific, Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.